Xibrom 0.09% and 0.18% formulations "nearly identical"

Article

A clinical trial of Xibrom (bromfenac sodium ophthalmic solution; ISTA Pharmaceuticals) has demonstrated equivalence of end-point achievement between the 0.18% and the 0.09% formulations, according to topline results published by ISTA Pharmaceuticals.

A clinical trial of Xibrom (bromfenac sodium ophthalmic solution; ISTA Pharmaceuticals) has demonstrated equivalence of end-point achievement between the 0.18% and the 0.09% formulations, according to topline results published by ISTA Pharmaceuticals.

The trial - conducted by ISTA in conjunction with the company's new drug application (NDA) for Xibrom QD (once-daily), submitted to the FDA in December 2007 - measured post-surgical absence of ocular inflammation. The 0.18% formulation is a new formulation of ISTA's ocular, non-steroidal anti-inflammatory agent (NSAID), FDA-approved in 2005 as a twice-daily treatment for inflammation and reduction of pain following cataract surgery.

The trial demonstrated nearly identical performance between the two formulations, suggesting that the 0.09% formulation may be closer to the peak of the dose-response curve than ISTA had previously suspected.

Following the study, the United States Attorney's Office of Buffalo (NY) has issued ISTA with a subpoena requesting documentation relating to promotional, educational and other activities concerning Xibrom 0.09%. ISTA has announced that it will co-operate fully with the subpoena, and will now discuss the implications of these results, including the possibility of changing the label of Xibrom 0.09% to once-daily, with the FDA.

As well as demonstrating equivalence between formulations of absence of ocular inflammation 15 days post-surgery, the trial findings also demonstrated no statistically significant difference between formulations in eliminating ocular pain and reducing inflammation. Both formulations were associated with a low incidence of adverse events.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.